Diabetes & Metabolism Journal

Original Articles

Complications
Targeting SLC25A33 Suppresses Vascular Smooth Muscle Cell Proliferation and Migration by Reducing Cytosolic mtDNA Levels: Implications for Occlusive Vascular Diseases: Daehoon Kim, Jieun Shin, Yeon-Kyung Choi, You Mie Lee, Keun-Gyu Park, Hyang Sook Kim, Jun-Kyu Byun; Diabetes Metab J. 2026;50(1):139-152. Published online July 30, 2025; DOI: https://doi.org/10.4093/dmj.2024.0632

3,599 View
109 Download
1 Web of Science

Abstract PDF Supplementary Material PubReader ePub: Background
Vascular smooth muscle cells (VSMCs) play a crucial role in the development of occlusive vascular diseases through abnormal proliferation and migration. This pathological behavior is closely associated with mitochondrial reactive oxygen species (ROS)-mediated mitochondrial DNA (mtDNA) damage. The mitochondrial carrier protein solute carrier family 25 member 33 (SLC25A33), essential for nucleoside transport, is integral to mtDNA production. This study aimed to investigate the effects of SLC25A33 inhibition on the proliferation and migration of VSMCs, as well as its impact on neointima formation.
Methods
VSMCs were isolated from the thoracic aorta of 4-week-old Sprague-Dawley rats. The effects of small interfering RNAinduced silencing of SLC25A33 mRNA on platelet-derived growth factor (PDGF)-induced proliferation and migration of VSMCs were analyzed. The in vivo effects of targeting the SLC25A33 gene on neointima formation were evaluated using a murine carotid artery ligation model by perivascularly applying Lenti-shSLC25A33 with Pluronic F-127 gel.
Results
First, we observed an upregulation of the SLC25A33 protein in the carotid artery ligation-induced neointima in mice. Silencing of SLC25A33 suppressed the PDGF-stimulated proliferation and migration of VSMCs and cell cycle progression. Knockdown of SLC25A33 inhibited PDGF-induced production of mtDNA and ROS, consequently inactivating the cyclic GMP-AMP synthesis (cGAS)-stimulator of interferon genes (STING)-TANK-binding kinase 1 (TBK1)-nuclear factor kappa B (NF-κB) pathway. Furthermore, the downregulation of SLC25A33 reduced carotid artery ligation-induced neointima in mice.
Conclusion
This study suggests that targeting SLC25A33 in VSMCs could be a novel therapeutic strategy to prevent occlusive vascular diseases.

Basic Research
Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification: Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee; Diabetes Metab J. 2024;48(1):83-96. Published online January 3, 2024; DOI: https://doi.org/10.4093/dmj.2022.0363

10,826 View
333 Download
20 Web of Science
21 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Glucagon-like peptide-1 receptor agonist (GLP-1RA), which is a therapeutic agent for the treatment of type 2 diabetes mellitus, has a beneficial effect on the cardiovascular system.
Methods
To examine the protective effects of GLP-1RAs on proliferation and migration of vascular smooth muscle cells (VSMCs), A-10 cells exposed to angiotensin II (Ang II) were treated with either exendin-4, liraglutide, or dulaglutide. To examine the effects of GLP-1RAs on vascular calcification, cells exposed to high concentration of inorganic phosphate (Pi) were treated with exendin-4, liraglutide, or dulaglutide.
Results
Ang II increased proliferation and migration of VSMCs, gene expression levels of Ang II receptors AT1 and AT2, proliferation marker of proliferation Ki-67 (Mki-67), proliferating cell nuclear antigen (Pcna), and cyclin D1 (Ccnd1), and the protein expression levels of phospho-extracellular signal-regulated kinase (p-Erk), phospho-c-JUN N-terminal kinase (p-JNK), and phospho-phosphatidylinositol 3-kinase (p-Pi3k). Exendin-4, liraglutide, and dulaglutide significantly decreased the proliferation and migration of VSMCs, the gene expression levels of Pcna, and the protein expression levels of p-Erk and p-JNK in the Ang II-treated VSMCs. Erk inhibitor PD98059 and JNK inhibitor SP600125 decreased the protein expression levels of Pcna and Ccnd1 and proliferation of VSMCs. Inhibition of GLP-1R by siRNA reversed the reduction of the protein expression levels of p-Erk and p-JNK by exendin-4, liraglutide, and dulaglutide in the Ang II-treated VSMCs. Moreover, GLP-1 (9-36) amide also decreased the proliferation and migration of the Ang II-treated VSMCs. In addition, these GLP-1RAs decreased calcium deposition by inhibiting activating transcription factor 4 (Atf4) in Pi-treated VSMCs.
Conclusion
These data show that GLP-1RAs ameliorate aberrant proliferation and migration in VSMCs through both GLP-1Rdependent and independent pathways and inhibit Pi-induced vascular calcification.

Citations

Citations to this article as recorded by

Intracellular Angiotensin-II Measurement in Streptozotocin-Induced Rat Vascular Smooth Muscle Cells and Its Relationship with Angiotensin-II Receptors
Zehra Çiçek, Kübra Akıllıoğlu, Zehra Gül Yaşar, Ayşe Doğan
The European Research Journal.2026; : 407. CrossRef
ATF4 in cardiovascular diseases: an emerging therapeutic target
Luning Qin, Ruolan Chen, Chao Huang, Xuezhe Wang, Qinghang Song, Zhaoqing Li, Xiaojian Xu, Zhijun Liu, Banghui Wang, Bing Li, Xian-Ming Chu
Biochemical Pharmacology.2026; 246: 117703. CrossRef
The Effect of GLP-1 Receptor Agonists on Reoperation Following Anterior Cervical Discectomy and Fusion
Nicholas C. Bank, Daniel Whittingslow, Sam Duggan, Joshua L. Morningstar, Douglas S. Weinberg
World Neurosurgery.2026; 206: 124751. CrossRef
Liraglutide Ameliorates Injury‐Related Vascular Repair by Activating Autophagy Through Modulation of the PI3K–mTOR Signaling Pathway
Zongyi Zhang, Guixian Wu, Chaozhi Xu, Shanqian Li, Yulin Zhang, Yue Hu, Wanhua Wu, Hongyu Ding, Yuling Liu, Yue Huang, Wenjun Lu, Meimei Zheng, Yue Zhang, Hongxian Wu, Lina Hu
The FASEB Journal.2026;[Epub] CrossRef
Association between glucagon-like peptide-1 receptor agonists and femur fracture risk in type 2 diabetes: A large-scale target trial emulation
Yao-Jen Chang, Chiou-Shann Fuh, Jie-Fan Chang, Meng-Ting Chen, Ming-Hsien Tsai
Bone.2026; 207: 117851. CrossRef
Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis
Mehmet Kanbay, Sama Mahmoud Abdel-Rahman, Mustafa Guldan, Lasin Ozbek, Nur I Genc, Ahmet B Ak, Adrian Covic, Hayri K Goren
Clinical Kidney Journal.2026;[Epub] CrossRef
GLP-1 Receptor Agonists and Cardiovascular Effects: Scoping Review with ☸️SAIMSARA

SAIMSARA Journal.2026;[Epub] CrossRef
Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
Thanansayan Dhivagaran, Fahad Butt, Luckshann Arunasalam, Isabel Bae, David Mikhail, Brendan K. Tao, Jim Shenchu Xie, Michael Balas, Marko Popovic, Edward Margolin
Neurology.2026;[Epub] CrossRef
Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension
Benoit Aguado, Thomas Lacoste-Palasset, Grégoire Ruffenach, Fabrice Bauer, Laurent Savale, Marc Humbert, David Montani, Fabrice Antigny
ERJ Open Research.2026; 12(3): 01479-2025. CrossRef
Letter to the Editor concerning “The diabetic shoulder: association between diabetes mellitus and adhesive capsulitis — a systematic review and meta-analysis”
Zhongliao Zeng, Jinkun Li, zechen zhang, Xiaolin Shi, Yifeng Yuan
International Orthopaedics.2026;[Epub] CrossRef
Acute GLP‐1 infusion in male adults lowers circulating angiotensin II without changing angiotensinogen, ACE, ACE2, or angiotensin‐(1–7) concentrations
Ali Asmar, Muskaan Akram, Charlotte M. Sorensen, Jesper K. Andresen, Boye L. Jensen
Physiological Reports.2026;[Epub] CrossRef
Cardiometabolic Crossroads: Obesity, Sleep-Disordered Breathing, and Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction – A Mini-Review
Fulvio Cacciapuoti, Ciro Mauro, Valentina Capone, Angelo Sasso, Luca Gaetano Tarquinio, Federico Cacciapuoti
Heart and Mind.2025; 9(2): 147. CrossRef
Perioperative Glucagon-Like Peptide-1 Agonist Use and Rates of Pseudarthrosis After Single-Level Lumbar Fusion: A Large Retrospective Cohort Study
Vedant Agrawal, Saketh Amasa, Mert Karabacak, Konstantinos Margetis
Neurosurgery.2025; 97(1): 91. CrossRef
ALOX15 Aggravates Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice with Type 2 Diabetes via Activating the PPARγ/CD36 Axis
Wenhui Yan, Xin Cui, Tingli Guo, Na Liu, Zhuanzhuan Wang, Yuzhuo Sun, Yuanrui Shang, Jieyun Liu, Yuanyuan Zhu, Yangyang Zhang, Lina Chen
Antioxidants & Redox Signaling.2025; 43(1-3): 37. CrossRef
Targeting the S100A9/P38 MAPK/HSPB1 axis as a novel approach for aortic dissection therapy
Likang Ma, Linfeng Xie, Qingsong Wu, Lei Jin, Jiakang Li, Lele Tang, Li Zhang, Liangwan Chen, Zhihuang Qiu
International Immunopharmacology.2025; 149: 114225. CrossRef
Involvement of miRNA-204 carried by the exosomes of macrophages in the AT2 receptor-mediated improvement of vascular calcification
Hui-Yu Bai, Xiao-Rui Lv, Hai-Bo Gu, Hui Li, Bao-Shuai Shan
Cellular and Molecular Life Sciences.2025;[Epub] CrossRef
Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease
Luxcia Kugathasan, Yarden Aronson, Vikas S. Sridhar, Huajing Ni, Jean-Philippe Ouimet, Christine P. Limonte, Shohinee Sarma, David Z. I. Cherney
Expert Review of Clinical Immunology.2025; 21(8): 1113. CrossRef
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation
Husam Abu-Nejim, Richard C. Becker
Current Atherosclerosis Reports.2025;[Epub] CrossRef
Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies
Youngwoo Jang, Eun-Jung Rhee, Sung Hee Choi
Endocrinology and Metabolism.2025; 40(5): 668. CrossRef
Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
Andrea Etrusco, Mislav Mikuš, Antonio D’Amato, Fabio Barra, Petar Planinić, Trpimir Goluža, Giovanni Buzzaccarini, Jelena Marušić, Mara Tešanović, Antonio Simone Laganà
Biomedicines.2024; 12(3): 653. CrossRef
BRCC36 regulates β-catenin ubiquitination to alleviate vascular calcification in chronic kidney disease
Yalan Li, Xiaoyue Chen, Yiqing Xiong, Xueqiang Xu, Caidie Xie, Min Min, Dongmei Liang, Cheng Chen, Huijuan Mao
Journal of Translational Medicine.2024;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search